TG Therapeutics Q3 net income $390.9 million; raises 2025 revenue guidance
TG Therapeutics reported third quarter 2025 total revenue of $161.7 million, up from $83.9 million a year earlier, and net income of $390.9 million, which includes a non-recurring income tax benefit of approximately $365.0 million. The company raised its full-year 2025 BRIUMVI U.S. net product revenue target to approximately $585 million and its global revenue target to approximately $600 million, and authorized a new $100 million share repurchase program.
Key points
- Q3 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million, versus $83.9 million total revenue in Q3 2024
- Net income of $390.9 million, including a non-recurring income tax benefit of approximately $365.0 million; operating income was $29.4 million
- Full-year 2025 BRIUMVI U.S. net product revenue target raised to approximately $585 million from $570-$575 million; global revenue target raised to approximately $600 million from $585 million
- Completed the prior $100 million share repurchase, buying about 3.5 million shares at an average $28.55; new $100 million program authorized
The filing
Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.